Last: | $1.44 |
---|---|
Change Percent: | -1.38% |
Open: | $1.47 |
Close: | $1.44 |
High: | $1.48 |
Low: | $1.39 |
Volume: | 135,955 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.44 | $1.47 | $1.44 | $1.48 | $1.39 | 135,955 | 04-26-2024 |
$1.45 | $1.45 | $1.45 | $1.47 | $1.4055 | 82,052 | 04-25-2024 |
$1.46 | $1.47 | $1.46 | $1.47 | $1.44 | 76,087 | 04-24-2024 |
$1.47 | $1.51 | $1.47 | $1.53 | $1.44 | 185,871 | 04-23-2024 |
$1.51 | $1.55 | $1.51 | $1.57 | $1.5 | 123,706 | 04-22-2024 |
$1.56 | $1.54 | $1.56 | $1.57 | $1.5 | 227,110 | 04-19-2024 |
$1.5 | $1.51 | $1.5 | $1.61 | $1.5 | 155,914 | 04-18-2024 |
$1.5 | $1.54 | $1.5 | $1.6 | $1.5 | 133,523 | 04-17-2024 |
$1.52 | $1.57 | $1.52 | $1.57 | $1.5 | 171,472 | 04-16-2024 |
$1.59 | $1.6 | $1.59 | $1.68 | $1.53 | 175,064 | 04-15-2024 |
$1.63 | $1.65 | $1.63 | $1.67 | $1.585 | 117,409 | 04-12-2024 |
$1.66 | $1.66 | $1.66 | $1.71 | $1.555 | 265,788 | 04-11-2024 |
$1.67 | $1.7 | $1.67 | $1.7 | $1.63 | 148,781 | 04-10-2024 |
$1.71 | $1.81 | $1.71 | $1.81 | $1.65 | 154,015 | 04-09-2024 |
$1.78 | $1.76 | $1.78 | $1.85 | $1.65 | 284,272 | 04-08-2024 |
$1.77 | $1.82 | $1.77 | $1.82 | $1.685 | 171,590 | 04-05-2024 |
$1.74 | $1.87 | $1.74 | $1.879 | $1.72 | 181,135 | 04-04-2024 |
$1.85 | $1.77 | $1.85 | $1.885 | $1.7438 | 140,978 | 04-03-2024 |
$1.79 | $1.81 | $1.79 | $1.82 | $1.69 | 243,390 | 04-02-2024 |
$1.83 | $1.91 | $1.83 | $1.91 | $1.71 | 188,017 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Cel-Sci Corporation Company Name:
CVM Stock Symbol:
NYSE Market:
CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as in...
CEL-4000 may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weakening important immune defense mechanisms, risking infections or cancer, as current treatments may CEL-SCI Corporation (NYSE American: CVM) today announced the peer rev...
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2023, as well as key recent clinical and corporate developments. Clinical and Corporate Developments include: CEL-SCI identified the target head and neck cancer patient popul...